International Journal of Hematology-Oncology and Stem Cell Research 2017. 11(2):139-147.

ABO Incompatibility and Hematopoietic Stem Cell Transplantation Outcomes
Mohammad Vaezi, Davoud Oulad Dameshghi, Maryam Souri, Seyed Amin Setarehdan, Kamran Alimoghaddam, Ardeshir Ghavamzadeh


Introduction:The increased risk of hemolytic reactions and erythrocyte recovery delay in ABO incompatible hematopoietic stem cell transplantation (HSCT) are well established. Effects of ABO incompatibility on other transplantation outcomes are evaluated in this study.

Subjects and Methods: We prospectively followed 501 patients undergoing allogeneic stem cell transplantation regarding their ABO compatibility groups for a median time of 34.7 months. Patients were studied in minor, major and bidirectional mismatched and matched groups.

Result: Mean survival time (OS) was lower in minor mismatched group (p-value= 0.017). Minor and bidirectional mismatched groups received significantly more packed cell units than matched group (p-value < 0.0001 and p-value =0.002, respectively).Mean number of platelet unit infusion was significantly more in major mismatched recipients than matched group (p- value=0.031). Death rate was much more than expected in minor mismatched group. Two cases of PRCA (pure red cell aplasia) were found in major mismatched group. No statistically significant difference was found in the incidence of acute GVHD, chronic GVHD, time to neutrophil recovery, relapse- free survival, non-relapse mortality and relapse rate among groups.

Conclusion:In order to prevent complications of ABO-incompatible SCT such as decrease in OS and the need for more transfusions, choosing ABO-compatible donors would improve transplantation outcomes.


ABO incompatibility; Allogeneic hematopoietic stem cell transplantation

Full Text:



Petz LD. Hemolysis associated with transplantation. Transfusion 1998; 38: 224-228.

StussiG, Muntwyler J, Passweg JR, et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2002; 30(2): 87-93.

Mielcarek M, Leisenring W, Torok-Storb B, et al. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood.2000; 96(3): 1150-1156.

Stussi G, Seebach L, Muntwyler J, et al. Graft-versus-host disease and survival after ABO-incompatible allogeneicbone marrow transplantation: a single-centre experience. Br J Haematol. 2001;113(1):251-3.

Canals C, Muñiz-Díaz E, Martínez C, et al. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.Transfusion. 2004;44(11):1603-11.

Kim JG, Sohn SK, Kim DH, et al. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.Bone Marrow Transplant. 2005;35(5):489-95.

Erker CG, Steins MB, Fischer RJ, et al. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation.Transfusion.2005; 45: 1382-90.

Rowley, S.D., Donato, M.L., Bhattacharyya, P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant.2011; 46: 1167–1185.

Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4): 295-304.

Singh R, Mukhopadhyay K. Survival analysis in clinical trials: Basics and must know areas. Perspect Clin Res. 2011; 2(4): 145–148.

M J Bradburn, T G Clark, S B Love, and D G Altman; Survival Analysis Part II: Multivariate data analysis – an introduction to concepts and methods. Br J Cancer. 2003 Aug 4; 89(3): 431–436.

SpruanceSL, Julia RE., Grace M, et al. Hazard Ratio in Clinical Trials. Antimicrob Agents Chemother. 2004; 48(8): 2787–2792.

Lasky LC, Warkentin PI, Kersey JH, et al. Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation. Transfusion.1983; 23: 277-285.

Ozkurt ZN, Yegin ZA, YenicesuI, et al. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.Transplant Proc. 2009;41(9):3851-8.

Logan AC, Wang Z, Alimoghaddam K, et al. ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(4):746-54.

Seebach JD, Stussi G, Passweg JR, et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant. 2005;11(12):1006-13.

Kimura F, Sato K, Kobayashi S,et al. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.Haematologica. 2008; 93(11):1686-93.

Benjamin RJ, McGurk S, Ralston MS, et al. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion.1999; 39: 179-187.

Kunimasa J, Yurugi K, Ito K, et al. Hemolytic reaction due to graft-versus-host (GVH) antibody production after liver transplantation from living donors: report of two cases. Surg Today. 1998; 28(8): 857-61.

Bacigalupo A, Van Lint MT, OcchiniD,et al. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation. 1988; 45(6):1091-4.

Veelken H, WäschR, Behringer D, et al. Pure red cell aplasia after allogeneic stem cell transplantation with reduced conditioning. Bone Marrow Transplant. 2000; 26(8):911-5.

Bolan CD, Leitman SF, Griffith LM, et al. Delayeddonor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation.Blood.2001; 98 (6):1687-94


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.